Fallopian Tube Cancer, Ovarian Cancer
Conditions
Keywords
stage I ovarian epithelial cancer, stage II ovarian epithelial cancer, stage III ovarian epithelial cancer, stage IV ovarian epithelial cancer, fallopian tube cancer
Brief summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether carboplatin and paclitaxel combined with gemcitabine is more effective than carboplatin and paclitaxel alone in treating ovarian epithelial or fallopian tube cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel combined with gemcitabine to see how well it works compared to paclitaxel and carboplatin alone in treating patients who have undergone surgery for ovarian epithelial or fallopian tube cancer.
Detailed description
OBJECTIVES: * Compare overall survival in patients with stage I-IV ovarian epithelial or fallopian tube cancer treated with adjuvant carboplatin and paclitaxel with or without gemcitabine. * Compare response rates, progression-free survival, and duration of response in patients treated with these regimens. * Compare toxic effects of these regimens in these patients. * Compare quality of life of patients treated with these regimens. OUTLINE: This is a randomized, open-label, controlled, multicenter study. Patients are stratified according to FIGO stage (I-IIA vs IIB-IIIC and tumor no greater than 10 mm vs IIB-IIIC and tumor greater than 10 mm or IV), plan for interval surgical debulking (yes vs no), and participating center. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive carboplatin IV over 30-60 minutes and paclitaxel IV over 3 hours on day 1 and gemcitabine IV over 30-60 minutes on days 1 and 8. * Arm II: Patients receive carboplatin and paclitaxel as in arm I. Treatment in both arms repeats every 21 days for 6 to 10 courses in the absence of disease progression or unacceptable toxicity. Some patients undergo interval debulking surgery. Quality of life is assessed at baseline, after courses 3 and 6, and then at 3, 6, and 12 months after completion of study. Patients are followed every 3 months for 2 years, every 6 months for up to 5 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 1,716 patients (858 per treatment arm) will be accrued for this study within 2 years.
Interventions
DRUGTCG
DRUGTC
Sponsors
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
GERCOR - Multidisciplinary Oncology Cooperative Group
AGO Study Group
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of one of the following: * Ovarian epithelial cancer * FIGO stage IA/B G3, IC-IV * Fallopian tube cancer * Extra-ovarian papillary serous tumor * The following are ineligible: * Low malignant-potential ovarian tumors (borderline tumors) * Non-epithelial ovarian tumors * Mixed Mullerian tumors * Must have had definitive surgery within the past 6 weeks * No symptomatic brain metastases PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 Life expectancy * At least 6 months Hematopoietic * WBC at least 3,000/mm\^3 OR * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Hemoglobin greater than 10 mg/dL Hepatic * Bilirubin no greater than 2 times upper limit of normal Renal * Glomerular filtration rate at least 50 mL/min Cardiovascular * No congestive heart failure * No myocardial infarction within the past 6 months * No New York Heart Association class III or IV heart disease * No prior atrial or ventricular arrhythmias Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No prior seizures or central nervous system disorder * No prior severe hypersensitivity reaction to products containing Cremophor EL (e.g., cyclosporine or vitamin K) * No known hypersensitivity to compounds chemically related to carboplatin, gemcitabine, or paclitaxel * No preexisting motor or sensory neuropathy greater than grade 1 * No other malignancy within the past 5 years except: * Malignancies cured by surgery alone * Carcinoma in situ of the cervix * Adequately treated basal cell skin cancer * No complete bowel obstruction * No other concurrent severe medical condition that would preclude study participation * No dementia or significantly altered mental status that would preclude study participation * No concurrent severe active infection * Geographically accessible for treatment and follow-up PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent immunotherapy Chemotherapy * No prior chemotherapy * No other concurrent chemotherapy Endocrine therapy * No concurrent hormonal therapy except: * Hormone replacement therapy * Antiemetic steroids Radiotherapy * No prior radiotherapy * No concurrent radiotherapy Surgery * See Disease Characteristics * Recovered from prior surgery Other * No other concurrent antineoplastic agents * No other concurrent investigational drugs * No other concurrent clinical trial enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | Whole Study Period | Survival time is calculated from the date of enrollment into the study until the date of death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | Whole Study Period | The progression-free survival is calculated for all patients from the date of enrollment until the date of first progressive disease or death, whichever occurs first |
Other
| Measure | Time frame |
|---|---|
| Quality of Life | Whole Study Period |
Countries
Denmark, France, Germany, Norway
Outcome results
None listed